Skip to Content

Press Releases

Press Releases

Data from Secondary Progressive Multiple Sclerosis Patient Treated with Intranasal Treatment with Foralumab will be Presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2022 Annual Meeting
Jun 01, 2022
Tiziana Life Sciences Ltd. Announces Annual Report Filed to Regain Nasdaq Compliance
May 24, 2022
Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference
Apr 26, 2022
FDA Grants Permission to Enroll up to 8 Additional Secondary Progressive Multiple Sclerosis (SPMS) Patients in the Expanded Access Program with Intranasal Foralumab
Apr 05, 2022
Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn’s Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
Mar 25, 2022
Tiziana Announces Availability of March 14 KOL Event Replay
Mar 15, 2022
Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Multiple Sclerosis
Mar 11, 2022
Tiziana Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Months with Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody
Mar 10, 2022
StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort
Mar 01, 2022
Tiziana Life Sciences CEO to Present at Annual BIO CEO & Investor Conference
Feb 10, 2022
Displaying 81 - 90 of 469